# EDGAR Filing Document

**Accession Number:** 0001421876
**File Stem:** 0001171843-26-001327
**Filing Date:** 2026-3
**Character Count:** 12739
**Document Hash:** 9de47355d27030d102d0be3519f53d50
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-001327.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001171843-26-001327

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260304

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GALAPAGOS NV
- **CENTRAL INDEX KEY:** 0001421876
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37384
- **FILM NUMBER:** 26721716

**BUSINESS ADDRESS:**
- **STREET 1:** GEN DE WITTELAAN L11 A3
- **CITY:** 2800 MECHELEN
- **STATE:** C9
- **ZIP:** 00000
- **BUSINESS PHONE:** 3215342900

**MAIL ADDRESS:**
- **STREET 1:** GEN DE WITTELAAN L11 A3
- **CITY:** 2800 MECHELEN
- **STATE:** C9
- **ZIP:** 00000

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026**

Commission File Number: **001-37384**

**GALAPAGOS NV**

(Translation of registrant's name into English)

**Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

------

On March 4, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[Exhibit 99.1. Press release dated March 4, 2026](exh_991.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>**&nbsp;&nbsp;&nbsp;&nbsp;GALAPAGOS NV&nbsp;&nbsp;&nbsp;&nbsp;**</u> |
|  | (Registrant) |
| Date: March 4, 2026 | <u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Annelies Denecker&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Annelies Denecker |
|  | Company Secretary |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Galapagos Receives Transparency Notifications from Bank of America**

**Mechelen, Belgium; March 4, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.**

Pursuant to Belgian transparency legislation<sup>1</sup>, Galapagos received transparency notifications on February 27 and March 2, 2026, from Bank of America Corporation. The initial notification indicates that Bank of America Corporation, as controlling entity, and its controlled entity, BofA Securities, Inc., individually crossed above the threshold of 5% of Galapagos' voting rights on February 26, 2026, including exceeding the threshold of 5% for equivalent financial instruments, as a result of an acquisition of Galapagos' equivalent financial instruments. Subsequently on March 2, Galapagos received a notification indicating that BofA Securities, Inc. fell below the 5% threshold of Galapagos' voting rights again on February 27, 2026 following the disposal of such instruments.

On March 2, 2026, Bank of America Corporation (taking into account the holding of its affiliates) owned 292,642 voting rights and 3,491,679 equivalent financial instruments, representing together 5.74% of Galapagos' currently outstanding 65,897,071 shares.

**Summary of the transactions:**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Date on which the threshold was crossed** | **Date of notification** | **Direct voting rights after the transaction** | **Equivalent financial instruments after the transaction** | **Total (%)** <br>**voting rights** |
| February 26, 2026 | February 27, 2026 | 0.20% | 5.49% | 5.69% |
| February 27, 2026 | March 2, 2026 | 0.44% | 5.30% | 5.74% |

---

**Content of the notifications from Bank of America Corporation:**

The notification dated March 2, 2026, contains the following information:

* Date of notification: March 2, 2026

* Date on which the threshold is crossed: February 27, 2026

* Threshold of voting rights crossed (in %): 5%

* Notification by: Bank of America Corporation

* Denominator: 65,897,071

* Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting
securities

* Notified details:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **A) Voting Rights** | **Previous notification** | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** |
| | **# of voting rights** | **# of voting rights** | **# of voting rights** | **% of voting rights** | **% of voting rights** |
| Holder of voting rights |  | Linked to securities | Not linked to securities | Linked to securities | Not linked to securities |
| Bank of America Corporation | 0 | 0 |  | 0.00% |  |
| Bank of America, National Association | 12440 | 12440 |  | 0.02% |  |
| Merrill Lynch International | 103934 | 95048 |  | 0.14% |  |
| Managed Account Advisors LLC | 3 | 3 |  | 0.00% |  |
| BofA Securities, Inc. | 0 | 170568 |  | 0.02% |  |
| Merrill Lynch, Pierce, Fenner & Smith <br>Incorporated | 14462 | 14462 |  | 0.00% |  |
| U.S. Trust Company of Delaware | 121 | 121 |  | 0.26% |  |
| **Subtotal** | 130960 | 292642 |  | 0.44% |  |
|  | **TOTAL** | **292642** | **0** | **0.44%** | **0.00%** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **B) Equivalent financial instruments** | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** |
| **Holder of equivalent financial instruments** | **Type of financial instrument** | **Expiration date** | **Exercise period or date** | **# of voting rights that may be acquired if the instrument is exercised** | **% of voting rights** | **Settlement** |
| Merrill Lynch International | Right to Recall |  |  | 141684 | 0.22% | physical |
| Merrill Lynch International | Rights of Use |  |  | 100 | 0.00% | physical |
| BofA Securities, Inc. | Right to Recall |  |  | 24700 | 0.04% | physical |
| BofA Securities, Inc. | Rights of Use |  |  | 3163290 | 4.80% | physical |
| Merrill Lynch International | Physical Call Option | 19/06/2026 |  | 100000 | 0.15% | physical |
| Bank of America, National Association | Swaps | 15/10/2027 |  | 36 | 0.00% | cash |
| Bank of America, National Association | Swaps | 31/01/2028 |  | 782 | 0.00% | cash |
| Bank of America, National Association | Swaps | 15/04/2027 |  | 14679 | 0.02% | cash |
| Bank of America, National Association | Swaps | 29/02/2028 |  | 741 | 0.00% | cash |
| Merrill Lynch International | Swaps | 15/01/2027 |  | 9167 | 0.01% | cash |
| Merrill Lynch International | Swaps | 30/04/2026 |  | 14350 | 0.02% | cash |
| Merrill Lynch International | Swaps | 02/07/2026 |  | 1113 | 0.00% | cash |
| Merrill Lynch International | Swaps | 01/11/2027 |  | 5726 | 0.01% | cash |
| Merrill Lynch International | Swaps | 15/04/2027 |  | 14679 | 0.02% | cash |
| Merrill Lynch International | Swaps | 15/10/2027 |  | 36 | 0.00% | cash |
| Merrill Lynch International | Swaps | 31/03/2027 |  | 596 | 0.00% | cash |
|  | **TOTAL** |  |  | **3491679** | **5.30%** |  |

---

---

| | | |
|:---|:---|:---|
| TOTAL (A&B) | **# of voting rights** | **% of voting rights** |
|  | **3784321** | **5.74%** |

---

The chain of control has been described at the end of the notification (section 11) and can be found here.

**Content of the notifications from Bank of America Corporation:**

The notification dated February 27, 2026, contains the following information:

* Date of notification: February 27, 2026

* Date on which the threshold is crossed: February 26, 2026

* Threshold of voting rights crossed (in %): 5%

* Notification by: Bank of America Corporation

* Denominator: 65,897,071

* Reason for the notification: Acquisition or disposal of financial instruments that are treated as voting
securities

* Notified details:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **A) Voting Rights** | **Previous notification** | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** |
| | **# of voting rights** | **# of voting rights** | **# of voting rights** | **% of voting rights** | **% of voting rights** |
| Holder of voting rights |  | Linked to securities | Not linked to securities | Linked to securities | Not linked to securities |
| Bank of America Corporation | 0 | 0 |  | 0.00% |  |
| Bank of America, National Association | 12481 | 12440 |  | 0.02% |  |
| Merrill Lynch International | 77455 | 103934 |  | 0.16% |  |
| Managed Account Advisors LLC | 3 | 3 |  | 0.00% |  |
| BofA Securities, Inc. | 0 | 0 |  | 0.00% |  |
| Merrill Lynch, Pierce, Fenner & Smith <br>Incorporated | 14462 | 14462 |  | 0.02% |  |
| U.S. Trust Company of Delaware | 121 | 121 |  | 0.00% |  |
| **Subtotal** | 104522 | 130960 |  | 0.20% |  |
|  | **TOTAL** | **130960** | **0** | **0.20%** | **0.00%** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **B) Equivalent financial instruments** | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** | **After the transaction** |
| **Holder of equivalent financial instruments** | **Type of financial instrument** | **Expiration date** | **Exercise period or date** | **# of voting rights that may be acquired if the instrument is exercised** | **% of voting rights** | **Settlement** |
| Merrill Lynch International | Right to Recall |  |  | 141684 | 0.22% | physical |
| BofA Securities, Inc. | Right to Recall |  |  | 24700 | 0.04% | physical |
| BofA Securities, Inc. | Rights of Use |  |  | 3289340 | 4.99% | physical |
| Merrill Lynch International | Physical Call Option | 19/06/2026 |  | 100000 | 0.15% | physical |
| Bank of America, National Association | Swaps | 31/01/2028 |  | 782 | 0.00% | cash |
| Bank of America, National Association | Swaps | 15/04/2027 |  | 14679 | 0.02% | cash |
| Bank of America, National Association | Swaps | 29/02/2028 |  | 736 | 0.00% | cash |
| Merrill Lynch International | Swaps | 15/01/2027 |  | 9167 | 0.01% | cash |
| Merrill Lynch International | Swaps | 30/04/2026 |  | 14310 | 0.02% | cash |
| Merrill Lynch International | Swaps | 02/07/2026 |  | 1106 | 0.00% | cash |
| Merrill Lynch International | Swaps | 01/11/2027 |  | 5726 | 0.01% | cash |
| Merrill Lynch International | Swaps | 27/02/2026 |  | 594 | 0.00% | cash |
| Merrill Lynch International | Swaps | 15/04/2027 |  | 14679 | 0.02% | cash |
| Merrill Lynch International | Swaps | 30/06/2026 |  | 12 | 0.00% | cash |
|  | **TOTAL** |  |  | **3617515** | **5.49%** |  |

---

---

| | | |
|:---|:---|:---|
| TOTAL (A&B) | **# of voting rights** | **% of voting rights** |
|  | **3748475** | **5.69%** |

---

The chain of control has been described at the end of the notification (section 11) and can be found here.

**About Galapagos**

Galapagos is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Galapagos prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit www.glpg.com or follow us on LinkedIn or X.

**For further information, contact Galapagos:**

**Investor Relations**

Glenn Schulman

+1 412 522 6239

ir@glpg.com

**Media**

Media

Katie Morris

+1 952 288 6821

katiemorris@ententeinc.com

Visit us at www.glpg.com or follow us on LinkedIn or X.

------

<sup>1</sup> Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions, as amended from time to time.